Clinical trials demonstrate that FMT combined with PD-1 inhibitors can effectively reverse primary resistance in advanced melanoma by remodeling the TME[159-161], representing a promising strategy to overcome immunotherapy resistance. This evidence concerns the gene PDCD1 and melanoma.